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To enable the synthesis of fl2-glycoprotein I mutants we have established a stable Chinese hamster ovary cell line that expresses human 82- 
glycoprotein I up to 2.9 ,ug/10 ~ cells/day. Recombinant fl2-glycoprotein I is identical to the purified native protein with respect to cofactor activity 
revealed in a modified anti-cardiolipin ELISA. Autoimmune type anti-cardiolipin antibody requires recombinant fl2-glycoprotein I in a dose- 
dependent manner to bind cardiolipin whilst binding of infectious type antibody is inhibited. The purified recombinant fl2-glycoprotein I in serum 
free medium exists as two oligosaccharide species which upon deglycosylation have identical apparent molecular weight o the deglycosylated native 
protein. 
fl2-glycoprotein I; Anti-cardiolipin antibody; Anti-phospholipid antibody 
1. INTRODUCTION 
fl2-Glycoprotein I is a highly glycosylated plasma 
protein comprised of 326 amino acids with an apparent 
molecular weight of about 50 kDa [1]. The complete 
nucleotide sequence of the human, rat, bovine and 
mouse fl2-glycoprotein I has been determined revealing 
a high degree of homology between species [2-8]. 
Current evidence suggests that fl2-glycoprotein I may 
function as a circulating anticoagulant as it inhibits con- 
tact activation of the intrinsic blood coagulation path- 
way [9], ADP-dependent aggregation of platelets [10], 
and prothrombinase activity of activated platelets [11]. 
fl2-Glycoprotein I is a cofactor in the recognition of 
the phospholipid antigen cardiolipin by anticardiolipin 
antibodies [12,13]. Anticardiolipin antibodies purified 
from patients with autoimmune disease require /~2- 
glycoprotein I to bind cardiolipin whilst anti-cardiolipin 
antibodies from patients with infection can bind cardi- 
olipin without the need for fl2-glycoprotein I [14,15]. 
The presence of anti-cardiolipin antibodies in patients 
with autoimmune disease confers an increased risk of 
thrombo-embolic omplications [16]; however the 
mechanism by which autoantibodies directed against a 
flz-glycoprotein I/phospholipid complex predisposes to 
thrombotic disorders is unknown. 
The analysis of mutant forms of flz-glycoprotein I 
would delineate the antigenic epitope(s) recognised by 
autoimmune anti-cardiolipin antibodies and as a first 
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step in that direction, we report the expression in trans- 
fected Chinese hamster cells of human recombinant//2- 
glycoprotein I.
2. MATERIALS AND METHODS 
The pB2C6 plasmid (6. l kb) was constructed by inserting the mouse 
dihydrofolate r ductase cDNA from the plasmic pSV2-dhfr (ATCC) 
into pB21-1 (pCDM8; Invitrogen) containing the full-length uman 
fl2-glycoprotein I cDNA (1.15 kb) which includes 5' and 3' untrans- 
lated regions and a putative leader sequence [2]. 
The pSV2-dhfr plasmid was double digested with PvuII and BamHI 
to produce the dihydrofolate reductase and SV40 promoter cDNA 
fragment (1.9 kb) which was then repaired to blunt ends. The pB21-1 
plasmid was double-digested with SeaI and StuI and the resulting 
large fragment (4.2 kb) ligated to the DHFR/SV40 fragment to form 
pB2C6 using standard techniques. The ligated DNA was used to 
transform E. coli MC1061 P3. 
The Chinese hamster ovary cell dihydrofolate reductase deficient 
mutant DG44 was propagated in c~ (Gibco) supplemented with 2% 
(v/v) heat-inactivated and dialysed fetal bovine serum, 50 U/ml penicil- 
lin, 50/lg/ml streptomycin, 0.1 mM hypoxanthine, 16 ,uM thymidine 
and 2 mM glutamine. Selection and amplification was performed 
using the same medium without hypoxanthine and thymidine and with 
the addition of methotrexate (Sigma) at concentrations indicated. 
pB2C6 DNA was transfected into DG44 cells (40 ,ug/106 cells) by 
the standard calcium phosphate precipitation technique [17]. Cells 
were grown in selective media for 1 week before addition ofmethotrex- 
ate at 0.1 ,uM. After 19 days selection, methotrexate-resistant colonies 
were picked using cloning cylinders into 24-well plates and the culture 
medium assayed for fl2-glycoprotein I production at confluency by 
radioimmunassay [14]. fl2-Glycoprotein I producing clones were in- 
noculated into 100 mm z petri dishes at the split ratio of 1:9 for a further 
25 days at 0.1 ¢tM methotrexate, followed by 19 days at 0.5/IM and 
finally 13 days at 2.5 ¢tM. High ~2-glycoprotein I secreting clones were 
weaned into serum free medium (Gibco; CHO-S-SFM) by sequentially 
decreasing the concentration of added dialysed fetal bovine serum. 
Cell populations in mid log growth phase were transferred to CHO- 
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S-SFM with 2% FBS, then 0.5% FBS and finally to CHO-S-SFM 
alone. 
Rabbit anti-fl2-glycoprotein I sera was affinity purified by the appli- 
cation of 45 ml of rabbit sera (immunised against native fl2-glycopro- 
tein I) to an Affigel-10 agarose gel (BioRad) coupled to 2.4 mg of 
native fl2-glycoprotein I. Affinity purified rabbit anti-fl2-glycoprotein 
I (1.5 mg) was coupled to 1.5 ml of Affi-prep hydrazide support 
according to manufacturers instructions (BioRad) and packed into a 
Pharmacia 5/5 column. Frozen serum free conditioned medium pooled 
from confluent cell cultures was thawed and the protease inhibitors 
traysol and N-ethylmaleimide added (final concentration of 1 U/ml 
and 1 mM, respectively). The medium was centrifuged at 3000 x g for 
15 min to remove cell debris and 5 M NaCI added to give a final 
concentration f0.5 M. Optimal flow rate through the affinity column 
was 0.05 ml/min via a 50 ml superloop attached to a Pharmacia FPLC 
system. The column was washed with 10 column volumes of 0.5 M 
NaCI/PBS at 0.25 ml/min and with 0.15 M NaCI/PBS at 1 ml/min 
before elution with 0.1 M glycine-HCl, pH 2.5, at 0.1 ml/min. The 
eluted 1 ml fractions were immediately neutralized with 2 M Tris, pH 
8.0, and pooled before adding sodium chloride and sodium acetate to 
give a final concentration of 0.05 M each for passage through a 
Pharmacia Mono S HR 5/5 cation exchange column as described 
previously [12]. 
A modification of the standard IgG cardiolipin ELISA with no 
serum-derived diluents or blocking agents was performed as previ- 
ously described [12]. 
Peptide:N-glycanase F (New England Biolabs) digestions were per- 
formed with 1000 U (NEB units) of enzyme on 1.5/lg of purified 
recombinant fl2-glycoprotein I and 6.5 fig of native flz-glycoprotein I. 
All samples were first denatured at100°C for 10 min in 0.5% SDS and 
1% mercaptoethanol before incubating at 37°C in 50 mM NaPO4 
buffer, pH 7.5, and 1% NP-40 for 18 h. SDS-PAGE was performed 
using slab gels with 10% polyacrylamide separating gel and 4% stack- 
ing gel and then silver stained. Western blotting was performed using 
Towbin transfer buffer overnight at 4°C and probed with 1/1000 
dilution of affinity purified rabbit anti-fl2-glycoprotein I and 1/1000 
dilution of sheep anti-rabbit alkaline phosphatase conjugated IgG. 
3. RESULTS 
Five pB2C6 transfected DG44 clones secreted flz- 
glycoprotein I into serum free culture medium at a rate 
between 0.25 and 2.9 I/g/106 cells/day in the absence of  
methotrexate. Recombinant  f lz-glycoprotein I was puri- 
fied from clone Y1B by immunoaff inity and elutes in the 
same fraction as native flz-glycoprotein I during car ion 
exchange chromatography.  The yield of  eluted fl2- 
glycoprotein I f rom the affinity column determined by 
rad io immunoassay was 60% but decreased to 44% after 
cation exchange. 
Amino-terminus equencing performed at Biotech 
Austral ia  confirmed that the first 18 amino acids of  the 
purified protein from the affinity column corresponded 
to fl2-glycoprotein I. Fol lowing cation exchange chrom- 
atography, two protein bands are revealed by SDS- 
PAGE and Western blot analyses (Fig. 1). Recombi-  
nant fl2-glycoprotein I gave a 61 kDa and a diffuse band 
of  50-56 kDa,  both bands being larger than native flz- 
glycoprotein I (49 kDa). They appear  to be glycoforms 
as digestion with peptide:N-glycosidase F which cleaves 
all N-l inked ol igosaccharides from asparagine residues 
resulted in a single diffuse band of  3642 kDa,  the main 
port ion of  which co-migrates with similarly digested 
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Fig. 1. SDS-PAGE (A) and Western blotting (B) analysis offl2-GPI. 
Purified recombinant (lanes 3,5) and native fl2-GPI (lanes 2,4) before 
(lanes 4,5) and after deglycosylation (lanes 2,3). PNGase F alone 
(lane 1) and molecular weight markers (lane 6; 97,66,43,31,21 kDa). 
native fl2-glycoprotein I (40 kDa). This size coincides 
with the deglycosylat ion study of  Walsh et al. [18]. 
In the modif ied IgG cardio l ip in-ELISA,  anti-cardiol-  
ipin antibodies from five auto immune patients purified 
using affinity and cation exchange chromatography [14] 
had an absolute requirement for recombinant  fl2- 
glycoprotein I in order to bind cardiol ipin (Fig. 2). 
Binding was dose dependent up to 8 ¢tg/ml, similar to 
native fl2-glycoprotein I (Fig. 3). In contrast, anti-cardi-  
ol ipin fractions purified by cation exchange from one 
patient with infection bound cardiol ipin without the 
need for recombinant  fl2-glycoprotein I (Fig. 2) and was 
not dose responsive (Fig. 3). 
4. D ISCUSSION 
Ant i -phosphol ip id  antibodies found in SLE and re- 
lated disorders are associated with thrombot ic  disease. 
The finding that f la-glycoprotein I constitutes part of  the 
antigen targetted by these antibodies has raised interest 
in the nature of  the epitope to which these auto-ant ibod-  
ies bind. Recently, there is evidence to suggest a l ipid 
binding site at the carboxy-terminus off l2-glycoprotein 
I [19,22]. The analysis and expression of mutants would 
delineate the sequences involved and we show here that 
the transfected Chinese hamster ovary cell line can syn- 
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Fig. 2. Modified IgG CL-ELISA (4 llg/ml aC1) for autoimmune (pa- 
tients 1 5) and infection group (patient 6) with and without fl2-GPI 
(8 pg/ml). N, no fl2-GPI; ~, native fl2-GPI; [], recombinant fl2-GPI. 
Results are the mean + S.E.M. of 3 samples. 
thesize fl2-glycoprotein I with cofactor activity and thus 
provide the means to accurately express fl2-glycoprotein 
I mutants. 
The difference in N-linked glycosylation between re- 
combinant and native fl2-glycoprotein I appears not be 
significant with respect to cofactor activity. Anti-cardi- 
olipin antibodies from autoimmune patients had an 
identical requirement for recombinant fl2-glycoprotein 
I to bind cardiolipin in EL1SA whilst infective type aCL 
kO 
O .q- 
/6  
I 4 
12 
: . 0 
08  
06  
04  
{32 
(}. '.3 
1 2 ,~ 4 
TF (! o, t~ tqq ~ KI [ 
Fig. 3. Dose-response of recombinant (1,3) and native (2,4)fl2-GPI 
at ([]) 0 ¢tg/ml, (N) 1 ,ug/ml, ([]) 2 ¢zg/ml, (Ill) 4 ¢tg/ml, (IN) 8 ,ug/ml 
against aCl (4 ,ug/ml) from one autoimmune patient (1,2) and one 
infection patient (3,4). Results are the mean _+ S.E.M. of 3 samples. 
antibodies did not, both findings previously described 
for native fl2-glycoprotein I [14,15]. In addition, there is 
evidence to suggest hat carbohydrate residues may not 
be important for anti-cardiolipin cofactor activity as all 
isoelectric subspecies of fl2-glycoprotein I with wide 
ranging pI have significant cofactor activity [19]. Most 
anticardiolipin antibodies, however, have a preference 
for human compared to bovine fl2-glycoprotein I [20] 
despite high homology (84%). A number of human fl2- 
glycoprotein isoforms have been described and there 
may be differences in the cofactor requirement of anti- 
cardiolipin antibodies for particular isoforms. 
Oligosaccharide processing amongst mammalian 
cells is species and cell type dependent and is also influ- 
enced by the cell culture environment (reviewed in [21]). 
We are investigating whether the oligosaccharide struc- 
ture of fl2-glycoprotein I differs when grown in serum 
containing medium and whether there are glycosylation 
differences between autoimmune and normal type fl2- 
glycoprotein I. 
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